# A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects

> **NCT01339897** · PHASE1 · COMPLETED · sponsor: **Nivalis Therapeutics, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 5 mg/N6022
- **DRUG:** Placebo
- **DRUG:** 10mg/N6022
- **DRUG:** 20mg/N6022

## Key facts

- **NCT ID:** NCT01339897
- **Lead sponsor:** Nivalis Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01339897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01339897, "A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01339897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*